The Latest Cardiac and Vascular News
– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – – Acceleron to host investor and analyst conference call and webcast with guest PAH […]
– Acceleron expects to report approximately $11.1 million in royalty revenue for Q2 2020 from approximately $55.0 million in net U.S. sales of REBLOZYL® (luspatercept-aamt) as reported by Bristol Myers Squibb – – Acceleron will report its full second quarter 2020 financial and operating results after the close of U.S. financial […]
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq: XLRN), a leading biopharmaceutical company in the discovery, development and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that it intends to offer and sell, subject to market and other conditions, $400 million of its common stock in an […]
Preclinical research of murine version of sotatercept reveals significant role of key TGF-beta superfamily proteins, including activin and growth differentiation factor ligands, in pulmonary vascular disease; points to therapeutic strategy in pulmonary arterial hypertension (PAH) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, […]
Sotatercept granted first FDA Breakthrough Therapy designation in pulmonary arterial hypertension since the Agency established the designation in 2012 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Acceleron Pharma Inc. (Nasdaq: XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that the […]
– REBLOZYL® (luspatercept-aamt), a first-in-class erythroid maturation agent, was approved by the U.S. FDA for the treatment of anemia in adult patients with beta-thalassemia who require regular red blood cell transfusions; FDA review of the sBLA for the lower-risk myelodysplastic syndromes indication is ongoing – – Multiple clinical presentations reviewed at the […]
